Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to 29.66%.

  • Collegium Pharmaceutical's EBITDA Margin rose 77900.0% to 29.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.74%, marking a year-over-year decrease of 115500.0%. This contributed to the annual value of 26.91% for FY2024, which is 25500.0% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported EBITDA Margin of 29.66% as of Q3 2025, which was up 77900.0% from 18.67% recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's EBITDA Margin ranged from a high of 41.2% in Q4 2023 and a low of 124.71% during Q4 2021
  • Moreover, its 5-year median value for EBITDA Margin was 19.78% (2021), whereas its average is 13.0%.
  • In the last 5 years, Collegium Pharmaceutical's EBITDA Margin tumbled by -1443700bps in 2021 and then soared by 1337800bps in 2022.
  • Collegium Pharmaceutical's EBITDA Margin (Quarter) stood at 124.71% in 2021, then surged by 107bps to 9.07% in 2022, then surged by 354bps to 41.2% in 2023, then plummeted by -49bps to 20.95% in 2024, then surged by 42bps to 29.66% in 2025.
  • Its EBITDA Margin stands at 29.66% for Q3 2025, versus 18.67% for Q2 2025 and 12.2% for Q1 2025.